Filing Flows

Filing Flows › Companies › Lexicon Pharmaceuticals › Cash flow

Lexicon Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$8.1M in Q3 2026 · −$49.2M over twelve months

Operating cash flow−$8.1M
Free cash flow−$8.1M
Cash conversion cycle-2423 days

Analysis

In Q3 2026, Lexicon Pharmaceuticals generated −$8.1M of operating cash flow. That is $15.8M more than in Q3 2025 (−$23.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$49.2M; the largest uses were other investing ($70.7M), net borrowing (+) / repaid (−) ($62.3M), operating cash flow ($49.2M); besides operations, cash came from shares issued ($97.8M), other financing ($52.7M); the cash balance fell by $34.6M.

Operating cash flow was −$8.1M against net income of −$14.0M. The largest differences: stock-based pay +$3.4M, payables +$2.9M, other non-cash −$724K.

Its cash conversion cycle was -2423 days (receivables 14 + inventory 1399 − payables 3836): suppliers fund its working capital.

Free cash flow

Lexicon Pharmaceuticals: free cash flow by quarterLexicon Pharmaceuticals: free cash flow by quarter−$22.0MQ4 2024−$43.8MQ1 2025$17.0MQ2 2025−$23.8MQ3 2025−$17.2MQ4 2025−$14.7MQ1 2026−$9.2MQ2 2026−$8.1MQ3 2026
Operating cash flow less capital spending.
Lexicon Pharmaceuticals: operating cash flow against capital spendingLexicon Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$21.5M$474KQ4 2024−$43.8M$0Q1 2025$17.0M$0Q2 2025−$23.8M$0Q3 2025−$17.2M$0Q4 2025−$14.7M$0Q1 2026−$9.2M$0Q2 2026−$8.1M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$8.1M, Capital spending $0.

Capital allocation, year by year

Lexicon Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearLexicon Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow −$87.0MFY2021: Net borrowing −$11.7MFY2021: Shares issued $37.1MFY2021: Capital spending −$1.2MFY2021: Buybacks −$2.7M$37.1MFY2021FY2022: Operating cash flow −$88.9MFY2022: Net borrowing $48.9MFY2022: Shares issued $94.2MFY2022: Capital spending −$1.3MFY2022: Buybacks −$864K$143MFY2022FY2023: Operating cash flow −$162MFY2023: Net borrowing $50.0MFY2023: Shares issued $139MFY2023: Capital spending −$470KFY2023: Buybacks −$824K$189MFY2023FY2024: Operating cash flow −$179MFY2024: Shares issued $241MFY2024: Capital spending −$1.0MFY2024: Buybacks −$1.7M$241MFY2024FY2025: Operating cash flow −$67.9MFY2025: Net borrowing −$48.0MFY2025: Shares issued $73K$73KFY2025
Over these 5 years operating cash flow totalled −$584M; the largest uses were operating cash flow ($584M) and net borrowing ($59.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$183M
Debt$51.9M
Net cash$131M
Cash runway3.7 years

Lexicon Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$49.2M a year at the current rate against $183M of cash and investments: a runway of about 3.7 years before any new financing.

Where the cash came from and went

Lexicon Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Lexicon Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other investing$11.2MOperating cash flow−$8.1MCash drawn (+) / kept (−)−$3.2MShares issued$55K
Lexicon Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Lexicon Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Shares issued$97.8MOther investing−$70.7MNet borrowing (+) / repaid (−)−$62.3MOther financing$52.7MOperating cash flow−$49.2MCash drawn (+) / kept (−)$34.6MTaxes on employees’ shares−$2.8M

From profit to cash

Lexicon Pharmaceuticals: net income to operating cash flow, Q3 2026Lexicon Pharmaceuticals: net income to operating cash flow, Q3 2026Net income−$14.0MDepreciation & amortization$95KStock-based pay$3.4MOther non-cash−$724KReceivables−$134KInventory−$10KPayables$2.9MPrepaid and other assets$475KOperating cash flow−$8.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20261413993836-2423
Q2 202688317176229-3629
Q1 2026302322533-2271
Q4 2025401001575-1435
Q3 202515150044602-43087
Q2 20257850922871-22284
Q1 2025181664838235-35771
Q4 2024111153834-3708

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$8.1M——$55K−$3.2M−$8.1M
Q2 2026−$9.2M—−$54.3M$1.0M$26.2M−$9.2M
Q1 2026−$14.7M—−$5.0M$96.6M−$3.8M−$14.7M
Q4 2025−$17.2M—−$3.0M$73K$15.3M−$17.2M
Q3 2025−$23.8M———−$28.3M−$23.8M
Q2 2025$17.0M—−$45.0M—$12.5M$17.0M
Q1 2025−$43.8M———$3.8M−$43.8M
Q4 2024−$21.5M−$474K—−$103K−$32.1M−$22.0M

Lexicon Pharmaceuticals: income statement and cash flow

Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%. The chart follows the revenue to costs, profit and cash.

Lexicon Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.